A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Public ClinicalTrials.gov record NCT02942290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Study identification
- NCT ID
- NCT02942290
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Azacitidine Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2017
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- May 17, 2026
2017 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155 | Tucson | Arizona | 85719-1478 | — |
| The University of Chicago Medical Center /ID# 153673 | Chicago | Illinois | 60637-1443 | — |
| University of Maryland, Baltimore /ID# 153669 | Baltimore | Maryland | 21201 | — |
| Tufts Medical Center /ID# 153672 | Boston | Massachusetts | 02111-1552 | — |
| Dana-Farber Cancer Institute /ID# 152735 | Boston | Massachusetts | 02215 | — |
| Washington University-School of Medicine /ID# 153671 | St Louis | Missouri | 63110 | — |
| Columbia University Medical Center /ID# 153661 | New York | New York | 10032-3729 | — |
| Weill Cornell Medical College /ID# 155524 | New York | New York | 10065 | — |
| Oregon Medical Research Center /ID# 152734 | Portland | Oregon | 97239 | — |
| University of Pittsburgh MC /ID# 153662 | Pittsburgh | Pennsylvania | 15260 | — |
| Tennessee Oncology-Nashville Centennial /ID# 222769 | Nashville | Tennessee | 37203-1632 | — |
| Vanderbilt University Medical Center /ID# 152738 | Nashville | Tennessee | 37232-0011 | — |
| UT MD Anderson Cancer Center /ID# 153809 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02942290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02942290 live on ClinicalTrials.gov.